Orexo

Orexo strengthens its sustainability work by establishing a social financing framework

Retrieved on: 
Friday, March 8, 2024
Second opinion, Substance abuse, International Capital Market Association, Carnegie Investment Bank, Overalls, Vaccine, VIVIsectVI, APLMA, ABG Sundal Collier, ICMA, Sustainalytics, Orexo, Loan Market Association, Online shopping

Additionally, Sustainalytics considers the Social Framework to be credible, impactful and to be aligned with the overall sustainability strategy of the Company and that the use of proceeds category will contribute to the advancement of UN Sustainable Development Goal 3 – Good Health and Wellbeing.

Key Points: 
  • Additionally, Sustainalytics considers the Social Framework to be credible, impactful and to be aligned with the overall sustainability strategy of the Company and that the use of proceeds category will contribute to the advancement of UN Sustainable Development Goal 3 – Good Health and Wellbeing.
  • The Social Framework and the Second Opinion are available on Orexos's website under the heading ESG Sustainable investing and Orexo intends to regularly report on the underlying social eligible projects which will be published on the Company's website.
  • ABG Sundal Collier AB and Carnegie Investment Bank have acted structuring advisors in connection to the establishment of the Social Framework.
  • As announced today in a separate press release, Orexo contemplates to issue new senior secured callable floating rate social bonds under the Social Framework.

Orexo strengthens its sustainability work by establishing a social financing framework

Retrieved on: 
Friday, March 8, 2024
Second opinion, Substance abuse, International Capital Market Association, Carnegie Investment Bank, Overalls, Vaccine, VIVIsectVI, APLMA, ABG Sundal Collier, ICMA, Sustainalytics, Orexo, Loan Market Association, Online shopping

Additionally, Sustainalytics considers the Social Framework to be credible, impactful and to be aligned with the overall sustainability strategy of the Company and that the use of proceeds category will contribute to the advancement of UN Sustainable Development Goal 3 – Good Health and Wellbeing.

Key Points: 
  • Additionally, Sustainalytics considers the Social Framework to be credible, impactful and to be aligned with the overall sustainability strategy of the Company and that the use of proceeds category will contribute to the advancement of UN Sustainable Development Goal 3 – Good Health and Wellbeing.
  • The Social Framework and the Second Opinion are available on Orexos's website under the heading ESG Sustainable investing and Orexo intends to regularly report on the underlying social eligible projects which will be published on the Company's website.
  • ABG Sundal Collier AB and Carnegie Investment Bank have acted structuring advisors in connection to the establishment of the Social Framework.
  • As announced today in a separate press release, Orexo contemplates to issue new senior secured callable floating rate social bonds under the Social Framework.

Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose

Retrieved on: 
Tuesday, November 28, 2023
NDA, ORX, Naloxone, Absorption, Fentanyl, US Foods, New Drug Application, Risk, Acceleration, Insurance, Patient, FDA, Orexo, Pain, Drug, PDUFA, OTC, Temperature, Pharmacy, Pharmaceutical industry

), (STO: ORX) (OTCQX: ORXOY), today announces the New Drug Application (NDA) for OX124 has been accepted for review by the US Food and Drug Administration (FDA).

Key Points: 
  • ), (STO: ORX) (OTCQX: ORXOY), today announces the New Drug Application (NDA) for OX124 has been accepted for review by the US Food and Drug Administration (FDA).
  • OX124 is a nasal rescue medication for opioid overdose containing a high dose of naloxone and is the first product based on Orexo´s world-class drug delivery platform, amorphOX®.
  • Nikolaj Sørensen, President and CEO, said: "I am pleased the FDA can now start reviewing our rescue drug, OX124.
  • I feel confident we can take advantage of these recent developments to reach many people acutely in need of more powerful overdose rescue medications.

Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose

Retrieved on: 
Tuesday, November 28, 2023
NDA, ORX, Naloxone, Absorption, Fentanyl, US Foods, New Drug Application, Risk, Acceleration, Insurance, Patient, FDA, Orexo, Pain, Drug, PDUFA, OTC, Temperature, Pharmacy, Pharmaceutical industry

), (STO: ORX) (OTCQX: ORXOY), today announces the New Drug Application (NDA) for OX124 has been accepted for review by the US Food and Drug Administration (FDA).

Key Points: 
  • ), (STO: ORX) (OTCQX: ORXOY), today announces the New Drug Application (NDA) for OX124 has been accepted for review by the US Food and Drug Administration (FDA).
  • OX124 is a nasal rescue medication for opioid overdose containing a high dose of naloxone and is the first product based on Orexo´s world-class drug delivery platform, amorphOX®.
  • Nikolaj Sørensen, President and CEO, said: "I am pleased the FDA can now start reviewing our rescue drug, OX124.
  • I feel confident we can take advantage of these recent developments to reach many people acutely in need of more powerful overdose rescue medications.

Orexo announces changes in the company´s Board of Directors

Retrieved on: 
Friday, October 27, 2023
Vaccine, Novo Nordisk, Wyeth, Protein, Drug development, Senior, Pfizer, Robin, ORX, Extraordinary general meeting, Orexo, Committee, Novo Holdings A/S, Fine chemical

), (STO: ORX) (OTCQX: ORXOY), announces that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S has become a member of the company´s Board of Directors.

Key Points: 
  • ), (STO: ORX) (OTCQX: ORXOY), announces that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S has become a member of the company´s Board of Directors.
  • Robin Evers replaces Henrik Kjaer Hansen, who has announced he will resign after having represented Orexo´s largest shareholder, Novo Holdings A/S, since 2018.
  • Henrik Kjaer Hansen will continue to work closely with Orexo as chairman of Orexo´s.
  • James Noble, Chairman of the Board of Directors, said: "Orexo has a strong track record of developing new drugs that have been approved in markets all over the world.

Orexo announces changes in the company´s Board of Directors

Retrieved on: 
Friday, October 27, 2023
Vaccine, Novo Nordisk, Wyeth, Protein, Drug development, Senior, Pfizer, Robin, ORX, Extraordinary general meeting, Orexo, Committee, Novo Holdings A/S, Fine chemical

), (STO: ORX) (OTCQX: ORXOY), announces that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S has become a member of the company´s Board of Directors.

Key Points: 
  • ), (STO: ORX) (OTCQX: ORXOY), announces that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S has become a member of the company´s Board of Directors.
  • Robin Evers replaces Henrik Kjaer Hansen, who has announced he will resign after having represented Orexo´s largest shareholder, Novo Holdings A/S, since 2018.
  • Henrik Kjaer Hansen will continue to work closely with Orexo as chairman of Orexo´s.
  • James Noble, Chairman of the Board of Directors, said: "Orexo has a strong track record of developing new drugs that have been approved in markets all over the world.

Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose

Retrieved on: 
Monday, September 18, 2023
US Foods, Partnership, Naloxone, New Drug Application, NDA, ORX, Orexo, Absorption, FDA, Opioid overdose, Fentanyl, Food, Cereal, Pharmaceutical industry

), (STO: ORX) (OTCQX: ORXOY), today announces the submission of the New Drug Application (NDA) to the US Food and Drug Administration (FDA) for OX124, a high-dose rescue medication for opioid overdose with nasal delivery.

Key Points: 
  • ), (STO: ORX) (OTCQX: ORXOY), today announces the submission of the New Drug Application (NDA) to the US Food and Drug Administration (FDA) for OX124, a high-dose rescue medication for opioid overdose with nasal delivery.
  • OX124, is based on Orexo´s world-class drug delivery platform amorphOX® and is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl.
  • [2] The great majority, 76 percent, refers to opioid overdoses, and of these 91 percent involved synthetic opioids.
  • Me and my team look forward to giving broad access to this important and differentiated medication."

Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose

Retrieved on: 
Monday, September 18, 2023
US Foods, Partnership, Naloxone, New Drug Application, NDA, ORX, Orexo, Absorption, FDA, Opioid overdose, Fentanyl, Food, Cereal, Pharmaceutical industry

), (STO: ORX) (OTCQX: ORXOY), today announces the submission of the New Drug Application (NDA) to the US Food and Drug Administration (FDA) for OX124, a high-dose rescue medication for opioid overdose with nasal delivery.

Key Points: 
  • ), (STO: ORX) (OTCQX: ORXOY), today announces the submission of the New Drug Application (NDA) to the US Food and Drug Administration (FDA) for OX124, a high-dose rescue medication for opioid overdose with nasal delivery.
  • OX124, is based on Orexo´s world-class drug delivery platform amorphOX® and is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl.
  • [2] The great majority, 76 percent, refers to opioid overdoses, and of these 91 percent involved synthetic opioids.
  • Me and my team look forward to giving broad access to this important and differentiated medication."

AdhereTech Appoints Innes Meldrum as President and Chief Executive Officer

Retrieved on: 
Wednesday, September 6, 2023
Argentum, Innes, Chairperson, Senior, CNS, Addiction medicine, Novartis, Patient, Growth, Commercial, Pharmaceutical industry, Management, Silver, Orexo

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- AdhereTech, Inc., a leading digital healthcare company focused on building cloud-based software and devices that seamlessly connect patients to care, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Key Points: 
  • NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- AdhereTech, Inc., a leading digital healthcare company focused on building cloud-based software and devices that seamlessly connect patients to care, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
  • Innes Meldrum has nearly 30 years of global experience in the pharmaceutical and technology industries.
  • He most recently served as Chief Executive Officer of Reset Pharmaceuticals.
  • Prior to this, he served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.

EQS-News: AdhereTech Appoints Innes Meldrum as President and Chief Executive Officer

Retrieved on: 
Wednesday, September 6, 2023
Argentum, Innes, Chairperson, Senior, CNS, Addiction medicine, Novartis, Patient, Growth, Commercial, Pharmaceutical industry, Management, Silver, Orexo

AdhereTech, Inc., a leading digital healthcare company focused on building cloud-based software and devices that seamlessly connect patients to care, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Key Points: 
  • AdhereTech, Inc., a leading digital healthcare company focused on building cloud-based software and devices that seamlessly connect patients to care, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
  • Innes Meldrum has nearly 30 years of global experience in the pharmaceutical and technology industries.
  • He most recently served as Chief Executive Officer of Reset Pharmaceuticals.
  • Prior to this, he served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.